ERPN: Product Development (Sub-Topic)最新文献

Improving New Product Development Using Big Data: A Case Study of an Electronics Company 利用大数据改进新产品开发:以某电子公司为例

ERPN: Product Development (Sub-Topic) Pub Date : 2017-09-01 DOI: 10.1111/radm.12242

K. Tan, Y. Zhan

{"title":"Improving New Product Development Using Big Data: A Case Study of an Electronics Company","authors":"K. Tan, Y. Zhan","doi":"10.1111/radm.12242","DOIUrl":"https://doi.org/10.1111/radm.12242","url":null,"abstract":"Big data is becoming more important to the new product development (NPD) efforts of global firms. Although the term of big data is not new, very few studies have investigated how firms can harvest big data to facilitate NPD. The purpose of this article is to present the means by which big data can be used to assist firms in NPD to shorten the time to market, improving customers’ product adoption and reducing costs. This research is based on a two-step approach. First, we identified and analysed three world-leading firms that have successfully integrated big data in supporting their NPD. Then, the observations from the firms were used to determine the principle involved in leveraging big data to reduce product development lead times and costs. Given the exploratory nature of the research objective, a participant-observation case study is adopted in which during a 6-month period a NPD project in a fast moving high-tech industry was investigated. This study provides empirical confirmation for the three principles to big data supported NPD: (a) Autonomy; (b) Connection; and (c) Ecosystem. It is termed the ACE principles which we believe represent a paradigm shift to help firms unlock the power of big data and make NPD faster and less costly. This article provides guideline to firms in harvesting big data to better support their NPD: it allows organisations to launch new products to market as quickly as possible; it helps organisations to determine the weaknesses of the product earlier in the development cycle; it allows functionalities to be added to a product that customers are willing to pay a premium for, while eliminating features they do not want; and it identifies and then prioritises customer needs for specific markets.","PeriodicalId":124257,"journal":{"name":"ERPN: Product Development (Sub-Topic)","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129354316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 63

Intellectual Property Protection Mechanisms in Collaborative New Product Development 协同新产品开发中的知识产权保护机制

ERPN: Product Development (Sub-Topic) Pub Date : 2016-07-01 DOI: 10.1111/radm.12126

R. Manzini, V. Lazzarotti

引用次数: 75

Turbulence in High Growth and Declining Industries 高增长和衰退行业的动荡

ERPN: Product Development (Sub-Topic) Pub Date : 2007-07-01 DOI: 10.2139/ssrn.1021203

R. Baptista, Murat Karaöz

引用次数: 17

Pharmaceutical Lemons: Innovation and Regulation in the Drug Industry 制药柠檬:制药行业的创新和监管

ERPN: Product Development (Sub-Topic) Pub Date : 2007-02-22 DOI: 10.31235/OSF.IO/5W8XS

Ariel Katz

{"title":"Pharmaceutical Lemons: Innovation and Regulation in the Drug Industry","authors":"Ariel Katz","doi":"10.31235/OSF.IO/5W8XS","DOIUrl":"https://doi.org/10.31235/OSF.IO/5W8XS","url":null,"abstract":"Before a new drug can be marketed the Food and Drug Administration must be satisfied that it is safe and effective. According to conventional wisdom, the cost and delay involved in this process diminish the incentives to invest in the development of new drugs. Accordingly, several reforms aimed at restoring such incentives have been implemented and others have been advocated. This paper challenges the central argument in the debate on the topic, namely that drug regulation and drug innovation are necessarily at odds with each other. Although intuitively appealing, the argument that drug regulation negatively affects the incentives to innovate does not fully capture the role that regulation plays in this industry. This paper shows that the regulatory framework is not solely a burden imposed on the industry; it also provides a valuable service to the industry. Specifically, drug regulation provides certification of drug quality. Such certification, which may not be easily achieved by private market-based mechanisms, prevents the market from becoming a market for \"lemons\". Therefore, rather than decreasing the expected returns to innovation, this aspect of regulation contributes to the value of new drugs and may actually encourage innovation. This point has largely been absent from most cost-benefit analyses of drug regulation, yet without it any discussion of the merits of regulation is incomplete.","PeriodicalId":124257,"journal":{"name":"ERPN: Product Development (Sub-Topic)","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2007-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125339675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 46

Defining Problems and Opportunities in New Product Development (Part 1) 定义新产品开发中的问题和机会(第一部分)

ERPN: Product Development (Sub-Topic) Pub Date : 1900-01-01 DOI: 10.2139/ssrn.3027027

Jeremy Hutchison-Krupat, R. Chao, Donald Stevenson

引用次数: 0